RxDoctor Payments Data

Chayeh Saunders, NP

Family · Baltimore, MDNPI 1659841971

Payments from drug & device makers

$7,301in general payments, 2019–2025

Across 403 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$767
  • Gilead$453
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$439
  • Takeda Pharmaceuticals U.S.A., Inc.$393
  • Pfizer$330
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$7,282100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,301 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$44,666
Medicare patients
219
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Yuflyma(Cf) (2 Pack)Adalimumab-Aaty11$145,415
CreonLipase/Protease/Amylase30$93,246
ZenpepLipase/Protease/Amylase12$64,813
Mesalamine15$7,338
Mesalamine ErMesalamine12$3,283
Pantoprazole Sodium185$2,764
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates35$1,963
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl78$1,077
Dicyclomine Hcl57$963
Omeprazole49$920
Famotidine41$779
Nadolol12$746
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl33$495
Ursodiol12$465
Lactulose13$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Celltrion USA Inc.Yuflyma(Cf) (2 Pack)$32$145,41511 claims
AbbVieCreon$2,848$93,24630 claims
Aimmune Therapeutics, Inc.Zenpep$204$64,81312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →